In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6

ISSN： 0028-1298

Source： Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.378, Iss.3, 2008-09, pp. : 275-282

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro

By Pan Yan Tiong Kai Abd-Rashid Badrul Ismail Zakiah Ismail Rusli Mak Joon Ong Chin

Journal of Natural Medicines, Vol. 68, Iss. 2, 2014-04 ,pp. : 402-406

Springer Publishing Company

Access to resources Recommend Favorite

Prediction of In Vivo Drug-Drug Interactions from In Vitro Data: Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4

By Brown Hayley S. Galetin Aleksandra Hallifax David Houston J. Brian

Clinical Pharmacokinetics, Vol. 45, Iss. 10, 2006-01 ,pp. : 1035-1050

Adis International

Access to resources Recommend Favorite

Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response

Current Pharmacogenomics, Vol. 3, Iss. 1, 2005-03 ,pp. : 43-52

Bentham Science Publishers

Access to resources Recommend Favorite

CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population

By Scott Stuart A Edelmann Lisa Kornreich Ruth Erazo Monica Desnick Robert J

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 721-730

Future Medicine

Access to resources Recommend Favorite

Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m‐hydroxymexiletine

Pharmacology Research & Perspectives, Vol. 3, Iss. 5, 2015-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite